STOCK TITAN

LifeStance (LFST) Insider Files Form 144 to Sell 226,518 Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 226,518 shares of common stock through Morgan Stanley & Co. LLC on 08/18/2025. The filing states an aggregate market value of $1,225,462.38 and reports 388,936,394 shares outstanding. The securities were acquired in a pre-IPO transaction on 06/10/2021, when 1,299,792 shares were obtained from the issuer; payment is noted as equity interests purchased pre-IPO. No sales by the reporting person in the past three months are disclosed. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider plans a routine secondary sale of 226,518 shares; size appears small relative to shares outstanding.

The Form 144 documents a proposed brokered sale of 226,518 common shares valued at $1.23 million on 08/18/2025 via Morgan Stanley. The position originated from a pre-IPO acquisition on 06/10/2021 totaling 1,299,792 shares. With 388,936,394 shares outstanding, the proposed sale represents a small percentage of the float, indicating this is likely a routine disposition rather than a material event for the company. The filing also confirms no related sales in the prior three months and includes the standard attestation regarding undisclosed material adverse information.

TL;DR: Disclosure follows Rule 144 mechanics; documentation shows pre-IPO origin and brokered execution.

The notice provides required Rule 144 details: acquisition date, nature of acquisition (pre-IPO), broker name and address, number of shares offered, and aggregate market value. The signer affirms lack of undisclosed material information and indicates no recent sales by the reporting person. From a governance perspective, the filing appears procedurally complete and compliant with Form 144 presentation requirements.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does LifeStance Health Group (LFST) report on this Form 144?

The filing reports a proposed sale of 226,518 common shares via Morgan Stanley on 08/18/2025, with an aggregate market value of $1,225,462.38.

When were the shares being sold originally acquired?

The shares were acquired on 06/10/2021 in a pre-IPO transaction from the issuer, totaling 1,299,792 shares acquired.

How many LifeStance shares are outstanding according to the filing?

The filing lists 388,936,394 shares outstanding.

Did the reporting person sell any LFST securities in the past three months?

The filing states: Nothing to Report for securities sold during the past three months by the reporting person.

Which broker is handling the proposed sale?

The broker named is Morgan Stanley & Co. LLC, 1585 Broadway, New York, NY 10036.